Omnicell (OMCL) Receives Buy Rating from Cantor Fitzgerald
Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating restated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They presently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 17.30% from the company’s previous close.
The analysts wrote, “On Wednesday, December 13, we hosted a series of investor meetings with Omnicell’s CFO, Peter Kuipers.””
Several other research firms also recently issued reports on OMCL. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Tuesday, December 5th. Craig Hallum restated a “buy” rating and set a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Finally, Benchmark increased their price objective on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $55.14.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.42. The firm had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.40 earnings per share. analysts predict that Omnicell will post 0.12 earnings per share for the current fiscal year.
In related news, VP Peter J. Kuipers sold 3,532 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $50.96, for a total value of $179,990.72. Following the sale, the vice president now owns 40,714 shares in the company, valued at $2,074,785.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Robin Gene Seim sold 9,780 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $48.97, for a total value of $478,926.60. Following the completion of the sale, the executive vice president now owns 55,896 shares in the company, valued at approximately $2,737,227.12. The disclosure for this sale can be found here. Insiders sold 38,944 shares of company stock worth $1,889,592 in the last quarter. 3.77% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of OMCL. Marco Investment Management LLC purchased a new stake in Omnicell during the third quarter valued at about $231,000. California Public Employees Retirement System raised its position in Omnicell by 6.2% during the third quarter. California Public Employees Retirement System now owns 86,240 shares of the company’s stock valued at $4,403,000 after purchasing an additional 5,040 shares in the last quarter. Janney Capital Management LLC raised its position in Omnicell by 45.3% during the third quarter. Janney Capital Management LLC now owns 9,484 shares of the company’s stock valued at $484,000 after purchasing an additional 2,957 shares in the last quarter. Synovus Financial Corp raised its position in Omnicell by 8.4% during the third quarter. Synovus Financial Corp now owns 21,009 shares of the company’s stock valued at $1,079,000 after purchasing an additional 1,623 shares in the last quarter. Finally, Pier Capital LLC purchased a new stake in Omnicell during the third quarter valued at about $5,488,000. Institutional investors own 99.85% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.